# ATF6 ameliorates renal warm ischemia-reperfusion injury through FHL2-mediated NF-κB signaling pathway

**Authors:** Xuan Wu, Ji-Hua Shi, Yang Bai, Dong-Jing Yang, Meng-Yao Jia, Dan-Feng Guo, Jia-Kai Zhang, Xiao-Yi Shi, Hua-Peng Zhang, Wen-Zhi Guo, Shui-Jun Zhang

PMC · DOI: 10.1016/j.isci.2026.115173 · 2026-02-28

## TL;DR

The study finds that ATF6 protects the kidneys from injury by reducing inflammation and regulating a key signaling pathway involving FHL2 and NF-κB.

## Contribution

The novel contribution is identifying ATF6 as a renoprotective factor through its regulation of the FHL2/NF-κB pathway in renal ischemia-reperfusion injury.

## Key findings

- ATF6 activation improves renal function and reduces inflammation in renal I/R injury.
- ATF6 represses FHL2 expression via direct promoter binding.
- ATF6 counteracts FHL2-mediated NF-κB activation, forming a protective signaling axis.

## Abstract

Renal ischemia-reperfusion (I/R) injury is a major cause of acute kidney injury and transplant dysfunction, involving endoplasmic reticulum stress. Although activating transcription factor 6 (ATF6) regulates ER stress resolution through the unfolded protein response, its specific role in renal I/R injury remains undefined. Here, we employed murine models of renal I/R and cellular hypoxia/reoxygenation (H/R) models to systematically investigate ATF6’s function. Our results show that I/R injury significantly upregulates ATF6 expression, particularly in proximal tubular epithelial cells. Functionally, ATF6 activation improved renal function and attenuated inflammation, whereas its inhibition exacerbated tubular damage. Mechanistically, we demonstrated that ATF6 transcriptionally represses four and a half LIM domain protein 2 (FHL2) through direct promoter binding. FHL2, in turn, interacts with TRAF6 to activate the nuclear factor kappa-B (NF-κB) pathway. ATF6 overexpression effectively counteracted FHL2-mediated NF-κB hyperactivation, establishing a protective ATF6/FHL2/NF-κB axis. These findings identify ATF6 as a key renoprotective factor and reveal mechanistic avenues for potential therapies targeting renal I/R injury and transplant complications.

•Renal I/R injury upregulates ATF6 in proximal tubular epithelial cells•ATF6 activation ameliorates renal function and attenuates inflammation•ATF6 transcriptionally represses FHL2 expression via direct promoter binding•ATF6 mitigates NF-κB activation by disrupting the FHL2-TRAF6 interaction

Renal I/R injury upregulates ATF6 in proximal tubular epithelial cells

ATF6 activation ameliorates renal function and attenuates inflammation

ATF6 transcriptionally represses FHL2 expression via direct promoter binding

ATF6 mitigates NF-κB activation by disrupting the FHL2-TRAF6 interaction

Physiology; Molecular biology

## Linked entities

- **Genes:** ATF6 (activating transcription factor 6) [NCBI Gene 22926], FHL2 (four and a half LIM domains 2) [NCBI Gene 2274], TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Diseases:** acute kidney injury (MONDO:0002492)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Atf6 (activating transcription factor 6) [NCBI Gene 226641] {aka 9130025P16Rik, 9630036G24, Atf6alpha, ESTM49}, Traf6 (TNF receptor-associated factor 6) [NCBI Gene 22034] {aka 2310003F17Rik, C630032O20Rik}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Fhl2 (four and a half LIM domains 2) [NCBI Gene 14200] {aka FHL-2, SLIM-3, SLIM3}
- **Diseases:** hypoxia (MESH:D000860), acute kidney injury (MESH:D058186), inflammation (MESH:D007249), transplant dysfunction (MESH:D007674), R (MESH:C580424), I/R injury (MESH:D015427), Renal ischemia-reperfusion (I/R) injury (MESH:D007511)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13019499/full.md

---
Source: https://tomesphere.com/paper/PMC13019499